With over 70% of American adults having overweight or obesity, access to effective, science-backed tools has never been more important
Our community is growing, and every shaker bottle, every rep, every tablet is a part of that unstoppable energy
Within 2-3 days of stopping: Acute sleep-deepening effects fade Sleep quality may feel slightly reduced compared to peak cycle benefits No withdrawal symptoms (DSIP has no documented withdrawal profile) Over 1-2 weeks off: Sleep quality gradually returns toward pre-cycle baseline Circadian rhythm improvements may partially persist the entrained patterns do not disappear overnight Some users report maintained sleep improvement for 7-10 days after stopping This period is useful for assessing the natural sleep baseline Why cycling matters: No tolerance to DSIP has been documented in clinical literature

In the Phase 3 ESSENCE trial for metabolic dysfunction-associated steatohepatitis (MASH), semaglutide 2.4 mg weekly produced a 28.7 percentage-point difference over placebo in MASH resolution without fibrosis worsening, and a 14.4 percentage-point difference over placebo in fibrosis improvement without MASH worsening with 32.7% of semaglutide-treated patients achieving both endpoints simultaneously
Its pro-angiogenic mechanism raises a theoretical concern about tumor growth promotion, described in the literature as "a double-edged sword." WADA has banned it as an unapproved substance